Leukemia patients who failed drug-free remission get another shot with asciminib combo

NCT ID NCT06368414

Recruiting now Disease control Sponsor: Korean Society of Hematology Source: ClinicalTrials.gov ↗

First seen Apr 09, 2026 · Last updated Apr 30, 2026 · Updated 2 times

Summary

This study tests whether adding asciminib to standard tyrosine kinase inhibitors (TKIs) can help people with chronic myeloid leukemia (CML) stop all medication and stay in remission. It includes 69 adults who have been on TKIs for at least 5 years but failed previous attempts to stop treatment. After taking the combo for a year, participants will stop both drugs and be monitored for sustained remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Gachon University Gil Medical Center
RECRUITING

Incheon, Incheon, 21565, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE